Medical Treatments for Obesity: What Does the Future Have in Store?
Emerging obesity therapies like retatrutide show promise in reducing weight and improving related complications, but long-term safety and access are key considerations.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpusSummary and findings
The paper reviews emerging obesity pharmacotherapies, including the triple agonist retatrutide, which achieved weight reductions exceeding 25%. It discusses the efficacy of these therapies in improving obesity-related complications beyond weight loss. The review emphasizes a phenotype-guided, complication-centric approach to obesity management.
Abstract
<h4>Context</h4>Obesity is a chronic relapsing disease associated with substantial morbidity, mortality, and health care costs. Contemporary obesity pharmacotherapies extend beyond weight reduction, with evidence for improvements across multiple obesity-related complications, supporting a shift toward phenotype-guided, complication-centric care.<h4>Evidence acquisition</h4>A systematic literature search of the Medline database using MeSH terms and keywords related to new-generation obesity pharmacotherapy was conducted to identify articles published between 2021 and 2026. Reference lists of relevant reviews were screened to identify additional eligible studies. Phase 2 and 3 clinical trials evaluating emerging obesity pharmacotherapies in adults and reporting outcomes, including weight loss and obesity-related complications, were included.<h4>Evidence synthesis</h4>Entero-pancreatic hormone-based therapies targeting GLP-1, GIP, amylin, and glucagon pathways demonstrate substantial efficacy beyond weight reduction. These hormones act through complementary mechanisms regulating appetite, energy balance, and metabolic homeostasis. GLP-1 based agents achieve approximately 10-15% weight loss, whereas agents targeting multiple pathways demonstrate greater efficacy. Tirzepatide, CagriSema, and amycretin achieved weight reductions exceeding 20% and the triple agonist retatrutide produced reductions exceeding 25%. Beyond weight loss, these agents improve glycemia, support diabetes prevention, and produce organ-specific benefits, including reduced cardiovascular events, improved heart failure symptoms, decreased obstructive sleep apnea severity, improvement of metabolic dysfunction-associated steatohepatitis, slowing chronic kidney disease progression, and reduced osteoarthritis-related pain.<h4>Conclusions</h4>Next-generation obesity pharmacotherapies represent a major advance in obesity management and support a treat-to-target approach prioritizing improvement in obesity-related complications and metabolic health. Effective implementation will require individualized therapy and attention to long-term safety, access, and equitable delivery of care.
Background
Obesity is a chronic disease with significant health impacts, necessitating effective management strategies. Traditional treatments have focused primarily on weight loss, but emerging therapies aim to address obesity-related complications. This study reviews new pharmacotherapies that target various hormonal pathways, potentially offering more comprehensive benefits.
Methods
The review conducted a systematic literature search of the Medline database for articles published between 2021 and 2026. It included phase 2 and 3 clinical trials evaluating new obesity pharmacotherapies in adults, focusing on outcomes like weight loss and improvements in obesity-related complications.
Results
The review found that entero-pancreatic hormone-based therapies, including retatrutide, demonstrate significant efficacy. Retatrutide achieved weight reductions exceeding 25%, while other agents like tirzepatide and CagriSema exceeded 20%. These therapies also improved glycemia, reduced cardiovascular events, and provided other organ-specific benefits.
Interpretation
The findings suggest that next-generation obesity pharmacotherapies offer substantial benefits beyond weight loss, aligning with a treat-to-target approach. However, the clinical significance of these outcomes depends on long-term safety and access. The review highlights the need for individualized therapy and equitable care delivery.
Key findings
- Retatrutide produced weight reductions exceeding 25%.
- GLP-1 based agents achieve approximately 10-15% weight loss.
- Tirzepatide, CagriSema, and amycretin achieved weight reductions exceeding 20%.
- These agents improve glycemia and support diabetes prevention.
- They produce organ-specific benefits, including reduced cardiovascular events and improved heart failure symptoms.
Limitations
- Long-term safety not fully addressed
- Equitable access to therapies is a concern
- Synthesis from multiple studies with varying designs
- Focus on phase 2 and 3 trials only